Navigation Links
Lotus Pharmaceuticals Announces Approval of Reverse Stock Split
Date:12/31/2010

BEIJING, Dec. 31, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company will effect a two-for-one reverse split of its common stock in order to meet minimum share price requirements in connection with its application to a national U.S. securities exchange. In connection with the reverse split, the number of authorized shares of the Company's common stock will be reduced from 200,000,000 to 100,000,000 and the number of shares outstanding will be reduced from 53,399,407 to approximately 26,699,704.

The reverse split will take effect at the open of business today, December 31, 2010, at which time every two (2) shares of Lotus' common stock issued and outstanding will be converted into one (1) share of common stock. The shares will commence trading today on the OTC Bulletin Board on a post-reverse split basis under the temporary ticker symbol "LTUSD." After 20 business days, the "D" will be removed and the stock will resume trading under the ticker symbol "LTUS." No fractional common shares will be issued as a result of the reverse split.

Mr. Zhongyi Liu, Lotus' Chairman and Chief Executive Officer, stated, "We are pleased to announce this reverse split, as it is an important step toward our goal of a national securities exchange listing. We believe that we initiated the process at an appropriate time and that it is in the best interests of our stockholders and the Company's future growth. With the reverse split approved, we are one step closer to completing the listing process."

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Ph: 415-690-7688Email: shen@lotuspharma.com Web: http://www.lotuspharma.comInvestor Relations:Dave Gentry, PresidentRedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 104Email: info@redchip.comWeb: http://www.redchip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Announces Change of Directors
2. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
3. Lotus Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2010 Financial Results
4. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. Lotus Pharmaceuticals Announces Two Senior Management Appointments
7. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
8. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
9. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
10. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
11. Lotus Pharmaceuticals Terminates SEDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 /PRNewswire/ ... Israel . This new business entity, Emosis Ltd, headquartered ... to research and development of novel assays complementing the mother company ... relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move starts ...
(Date:3/28/2017)... FRANCISCO , March 28, 2017 ...  is expected to reach a value of USD 4.5 ... Grand View Research, Inc. Proper closure of injured tissues ... structure and function. Postoperative leakages occur in 3% to ... complication. They are responsible for one third of postoperative ...
(Date:3/27/2017)... 2017 Summary This report ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Public relations pros ... across a variety of business channels. , While many results are clear, much of ... relations program. , When it comes to measurement, firms should always take an ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco ... blog post about women’s hair loss. Although hair transplant procedures can be seen as ... Menopause or genetics can be two reasons a woman may see her hair thinning. ...
(Date:3/28/2017)... St. Louis, MO (PRWEB) , ... March 28, ... ... high levels of job satisfaction in their profession as their value increases in ... a company that provides resources such as job boards, career fairs, and candidate ...
Breaking Medicine News(10 mins):